Pharmacological correction of misfolding of ABC proteins☆

[1]  David Y. Thomas,et al.  Carbamazepine as a Novel Small Molecule Corrector of Trafficking-impaired ATP-sensitive Potassium Channels Identified in Congenital Hyperinsulinism* , 2013, The Journal of Biological Chemistry.

[2]  T. Uchiumi,et al.  Mutation and functional analysis of ABCC2/multidrug resistance protein 2 in a Japanese patient with Dubin–Johnson syndrome , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  G. Leftheriotis,et al.  The molecular and physiological roles of ABCC6: more than meets the eye , 2012, Front. Gene..

[4]  C. Cremer,et al.  Localization Microscopy (SPDM) Reveals Clustered Formations of P-Glycoprotein in a Human Blood-Brain Barrier Model , 2012, PloS one.

[5]  D. Cassio,et al.  Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. , 2012, Journal of hepatology.

[6]  Tudor I. Oprea,et al.  A Novel Flow Cytometric HTS Assay Reveals Functional Modulators of ATP Binding Cassette Transporter ABCB6 , 2012, PloS one.

[7]  Simon C Watkins,et al.  Pharmacological Rescue of the Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Detected by Use of a Novel Fluorescence Platform , 2012, Molecular medicine.

[8]  J. Schuetz,et al.  ABC transporters and their role in nucleoside and nucleotide drug resistance. , 2012, Biochemical pharmacology.

[9]  L. Wojnowski,et al.  Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells , 2012, Human mutation.

[10]  C. Ehrhardt,et al.  New fluorescent bile acids: synthesis, chemical characterization, and disastereoselective uptake by Caco-2 cells of 3-deoxy 3-NBD-amino deoxycholic and ursodeoxycholic acid. , 2012, Bioorganic & medicinal chemistry.

[11]  A S Verkman,et al.  CFTR: folding, misfolding and correcting the ΔF508 conformational defect. , 2012, Trends in molecular medicine.

[12]  K. Du,et al.  Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.

[13]  V. Haufroid,et al.  Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition , 2011, Pharmacogenetics and genomics.

[14]  John M. Knapp,et al.  Cyanoquinolines with Independent Corrector and Potentiator Activities Restore ΔPhe508-Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Function in Cystic Fibrosis , 2011, Molecular Pharmacology.

[15]  T. Ishikawa,et al.  Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts. , 2011, Journal of pharmaceutical sciences.

[16]  Wayne F. Patton,et al.  Sensitive and Specific Fluorescent Probes for Functional Analysis of the Three Major Types of Mammalian ABC Transporters , 2011, PloS one.

[17]  N. Pedemonte,et al.  Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. , 2011, American journal of physiology. Cell physiology.

[18]  P. Kris-Etherton,et al.  Development of a cell-based, high-throughput screening assay for cholesterol efflux using a fluorescent mimic of cholesterol. , 2011, Assay and drug development technologies.

[19]  Zahida Parveen,et al.  Molecular Dissection of Dual Pseudosymmetric Solute Translocation Pathways in Human P-Glycoprotein , 2011, Molecular Pharmacology.

[20]  Jan Ellenberg,et al.  Micropilot: automation of fluorescence microscopy–based imaging for systems biology , 2011, Nature Methods.

[21]  A. Holzinger,et al.  Some ABCA3 mutations elevate ER stress and initiate apoptosis of lung epithelial cells , 2011, Respiratory research.

[22]  J. Lehár,et al.  Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators. , 2010, Assay and drug development technologies.

[23]  C. Harding.  New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride , 2010, Biologics : targets & therapy.

[24]  J. Riordan,et al.  Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[25]  E. Boerwinkle,et al.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.

[26]  Balázs Sarkadi,et al.  Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays. , 2009, Advanced drug delivery reviews.

[27]  J. Riordan,et al.  CFTR function and prospects for therapy. , 2008, Annual review of biochemistry.

[28]  Tudor I. Oprea,et al.  High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. , 2008, Assay and drug development technologies.

[29]  Richard J. Thompson,et al.  Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. , 2008, Gastroenterology.

[30]  B. Sarkadi,et al.  Combined localization and real-time functional studies using a GFP-tagged ABCG2 multidrug transporter. , 2008, Biochemical and biophysical research communications.

[31]  Tudor I. Oprea,et al.  High-Throughput Screening for Daunorubicin-Mediated Drug Resistance Identifies Mometasone Furoate as a Novel ABCB1-Reversal Agent , 2008, Journal of biomolecular screening.

[32]  G. Szakács,et al.  Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. , 2006, Physiological reviews.

[33]  James Rader,et al.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[34]  J. Lupski,et al.  ABCA4 mutations causing mislocalization are found frequently in patients with severe retinal dystrophies. , 2005, Human molecular genetics.

[35]  G. Lukács,et al.  Antibodies for CFTR studies. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[36]  Y. Sugiyama,et al.  Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. , 2002, Advanced drug delivery reviews.

[37]  Zhe-Sheng Chen,et al.  Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). , 2002, Cancer research.

[38]  B. Sarkadi,et al.  Loss of ATP-dependent Transport Activity in Pseudoxanthoma Elasticum-associated Mutants of Human ABCC6 (MRP6)* , 2002, The Journal of Biological Chemistry.

[39]  B. Rothen‐Rutishauser,et al.  P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[40]  N. Dokholyan,et al.  Correctors of F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein , 2014 .

[41]  I. Ieiri.  Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). , 2012, Drug metabolism and pharmacokinetics.

[42]  B. Sarkadi,et al.  Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane. , 2011, Biochimica et biophysica acta.

[43]  G. Lukács,et al.  CFTR Folding Consortium: methods available for studies of CFTR folding and correction. , 2011, Methods in molecular biology.

[44]  C. Conrad,et al.  Functional genomics assays to study CFTR traffic and ENaC function. , 2011, Methods in molecular biology.